Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK negative
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
EML4-ALK variant 3 + TP53 mutation (5)
ALK fusion + ALK G1202R (4)
TP53 mutation + ALK positive (4)
ALK rearrangement + MET amplification (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
EML4-ALK fusion + ALK F1174L + ALK S1189C (3)
EML4-ALK fusion + ALK positive (3)
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L (3)
RANBP2-ALK rearrangement + TNFRSF8 expression (3)
ALK fusion + TP53 mutation (2)
ALK positive + ALK mutation (2)
ALK rearrangement + PD-L1 overepxression (2)
EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)
EML4-ALK fusion + ALK G1202R (2)
EML4-ALK fusion + ALK rearrangement (2)
EML4-ALK fusion + TP53 mutation (2)
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)
MYC amplification + ALK F1174L (2)
MYCN amplification + ALK F1174V (2)
MYCN amplification + ALK rearrangement (2)
STRN-ALK fusion + MET amplification (2)
ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion (1)
ALK expression + RSRC1-ALK fusion (1)
ALK fusion + ALK G1269A (1)
ALK fusion + ALK I1179T (1)
ALK fusion + ALK V1180L (1)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)
ALK fusion + FAT3 mutation (1)
ALK fusion + FAT4 mutation (1)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK mutation + TMB-H (1)
ALK negative + S100A8 elevation (1)
ALK negative + S100A9 elevation (1)
ALK negative + SAA1 elevation (1)
ALK negative + SAA2 elevation (1)
ALK negative + TP53 deletion (1)
ALK positive + ALK G1202R (1)
ALK positive + ALK G1202R + ALK L1196M (1)
ALK positive + ALK L1196M + ALK D1203N (1)
ALK positive + DNMT3A N403Tfs* (1)
ALK positive + EML4-ALK fusion + TP53 mutation (1)
ALK positive + ERCC3 E259D + GNAS A436_P459del (1)
ALK positive + MYC amplification + CCND1 deletion (1)
ALK psoitive + ALK G1202R + ALK F1174C (1)
ALK rearrangement + ABCC11 overexpression (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
ALK rearrangement + BRCA2 F2801fs (1)
ALK rearrangement + CDKN2A deletion (1)
ALK rearrangement + CDKN2B deletion (1)
ALK rearrangement + CTLA4 overexpression (1)
ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion (1)
ALK rearrangement + MET amplification (1)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BCL2L11 deletion + ALK positive (1)
CPE-ALK fusion + TP53 wild-type (1)
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)
EGFR exon 19 deletion + STRN-ALK fusion (1)
EGFR mutation + ALK negative + TMB-H (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
EML4-ALK fusion + ALK I1171N (1)
EML4-ALK fusion + ALK I1171T (1)
EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification (1)
EML4-ALK fusion + TMB-L (1)
EML4-ALK fusion v1insLTBP1 (1)
IDH2 mutation + ALK fusion (1)
KIF5B-ALK fusion + ALK L1196M (1)
MET amplification + KLC1-ALK fusion (1)
MET exon 14 mutation + ALK wild-type (1)
MYCN amplification + ALK F1174L (1)
MYCN amplification + ALK R1275Q (1)
PIK3CA mutation + ALK fusion (1)
PIK3CA mutation + ALK positive (1)
PTEN mutation + ALK positive (1)
SLC8A1-PKDCC-ALK fusion + ALK overexpression (1)
SMARCA4 mutation + ALK positive (1)
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)
STRN-ALK fusion + KRAS G13D (1)
TMB-H + ALK rearrangement (1)
TPM3-NTRK1 fusion + ALK L1196M (1)
PD-L1 underexpression + ALK wild-type (0)
EML4-ALK variant 3 + TP53 mutation (5)
ALK fusion + ALK G1202R (4)
TP53 mutation + ALK positive (4)
ALK rearrangement + MET amplification (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
EML4-ALK fusion + ALK F1174L + ALK S1189C (3)
EML4-ALK fusion + ALK positive (3)
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L (3)
RANBP2-ALK rearrangement + TNFRSF8 expression (3)
ALK fusion + TP53 mutation (2)
ALK positive + ALK mutation (2)
ALK rearrangement + PD-L1 overepxression (2)
EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)
EML4-ALK fusion + ALK G1202R (2)
EML4-ALK fusion + ALK rearrangement (2)
EML4-ALK fusion + TP53 mutation (2)
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)
MYC amplification + ALK F1174L (2)
MYCN amplification + ALK F1174V (2)
MYCN amplification + ALK rearrangement (2)
STRN-ALK fusion + MET amplification (2)
ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion (1)
ALK expression + RSRC1-ALK fusion (1)
ALK fusion + ALK G1269A (1)
ALK fusion + ALK I1179T (1)
ALK fusion + ALK V1180L (1)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)
ALK fusion + FAT3 mutation (1)
ALK fusion + FAT4 mutation (1)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK mutation + TMB-H (1)
ALK negative + S100A8 elevation (1)
ALK negative + S100A9 elevation (1)
ALK negative + SAA1 elevation (1)
ALK negative + SAA2 elevation (1)
ALK negative + TP53 deletion (1)
ALK positive + ALK G1202R (1)
ALK positive + ALK G1202R + ALK L1196M (1)
ALK positive + ALK L1196M + ALK D1203N (1)
ALK positive + DNMT3A N403Tfs* (1)
ALK positive + EML4-ALK fusion + TP53 mutation (1)
ALK positive + ERCC3 E259D + GNAS A436_P459del (1)
ALK positive + MYC amplification + CCND1 deletion (1)
ALK psoitive + ALK G1202R + ALK F1174C (1)
ALK rearrangement + ABCC11 overexpression (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
ALK rearrangement + BRCA2 F2801fs (1)
ALK rearrangement + CDKN2A deletion (1)
ALK rearrangement + CDKN2B deletion (1)
ALK rearrangement + CTLA4 overexpression (1)
ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion (1)
ALK rearrangement + MET amplification (1)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BCL2L11 deletion + ALK positive (1)
CPE-ALK fusion + TP53 wild-type (1)
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)
EGFR exon 19 deletion + STRN-ALK fusion (1)
EGFR mutation + ALK negative + TMB-H (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
EML4-ALK fusion + ALK I1171N (1)
EML4-ALK fusion + ALK I1171T (1)
EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification (1)
EML4-ALK fusion + TMB-L (1)
EML4-ALK fusion v1insLTBP1 (1)
IDH2 mutation + ALK fusion (1)
KIF5B-ALK fusion + ALK L1196M (1)
MET amplification + KLC1-ALK fusion (1)
MET exon 14 mutation + ALK wild-type (1)
MYCN amplification + ALK F1174L (1)
MYCN amplification + ALK R1275Q (1)
PIK3CA mutation + ALK fusion (1)
PIK3CA mutation + ALK positive (1)
PTEN mutation + ALK positive (1)
SLC8A1-PKDCC-ALK fusion + ALK overexpression (1)
SMARCA4 mutation + ALK positive (1)
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)
STRN-ALK fusion + KRAS G13D (1)
TMB-H + ALK rearrangement (1)
TPM3-NTRK1 fusion + ALK L1196M (1)
PD-L1 underexpression + ALK wild-type (0)
›
Associations
(4)
News
Trials
Search handles
@Tony_Calles
@ixazebe
@ns_chd
@timfenske
Search handles
@Tony_Calles
@ixazebe
@ns_chd
@timfenske
Filter by
Latest
1year
ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma | Blood | American Society of Hematology https://t.co/r3X6TfGAVp (@ixazebe)
1 year ago
ALK (Anaplastic lymphoma kinase) • JAK2 (Janus kinase 2)
|
ALK negative • JAK2 rearrangement
2years
Great work by @FordePatrick & colleagues. This trial has now established clear role for #immunotherapy in almost all stages of #EGFR/#ALK negative #NSCLC (early-stage neoadjuvant; early-stage adjuvant; locally advanced; metastatic). #PDL1 expression correlated w/ outcomes in all! (@ns_chd)
2 years ago
Clinical • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • ALK negative
2years
Based on the recent neo-adjuvant data and approval of Chemo-IO (#CM816) for Stage Ib-IIIA NSCLC, EGFR/ALK negative, what would you be doing in your clinical practice? In neo-adj settings, would you offer: #LCSM @FordePatrick @n8pennell @CharuAggarwalMD @JackWestMD @DrJNaidoo (@OncBrothers)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
ALK negative
2years
Similar situation now with a 50 yo male former smoker, no other comorbidities. lung adenocarcinoma, EGFR/ALK negative, PD-L1 20%. Stage IIIB (T4N2 by 7th and 8th AJCC Ed) VATS RUL lobectomy after neoadjuvant chemo-IO. pCR Remains NED (cc’d @DoctorJSpicer: again no N2 pics 🙏) (@Tony_Calles)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 negative • ALK negative
almost3years
IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY. Largest study to date... no impact of DUSP22 rearr on PFS. #16icml https://t.co/JI27UQtgUx (@timfenske)
almost 3 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK negative
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login